Summary & Overview
HCPCS Q5099: Injection, ustekinumab-stba (Steqeyma), biosimilar, 1 mg
HCPCS Level II code Q5099 denotes the administration of ustekinumab-stba (Steqeyma), a biosimilar formulation of the monoclonal antibody ustekinumab, reported per 1 mg. This code matters nationally as biologic therapies and their biosimilars are central to treatment of immune-mediated inflammatory conditions and represent a significant portion of specialty drug spend. Accurate coding affects billing, coverage determinations, inventory tracking, and pharmacovigilance reporting.
Key payers in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise review of the code's clinical context and typical sites of service, followed by benchmarking and payer coverage considerations where available. The publication summarizes common modifiers and implementation considerations relevant to claims processing for biosimilar injections.
Readers will learn: what Q5099 represents clinically; where and how the service is typically delivered; which major payers commonly process claims for this service; and what documentation and billing elements are commonly associated with biologic injection billing. Data not available in the input are noted where applicable.
Billing Code Overview
HCPCS Level II code Q5099 represents an injection of ustekinumab-stba (Steqeyma), biosimilar, 1 mg. This code is used to report the administered biologic product dose for patients receiving the biosimilar formulation of ustekinumab.
Service type: Therapeutic injection of a biologic (monoclonal antibody biosimilar).
Typical site of service: Outpatient infusion or injection clinic, physician office, or ambulatory care setting, where biologic injections or subcutaneous administrations are performed.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 42-year-old patient with moderate-to-severe plaque psoriasis requires maintenance biologic therapy with a ustekinumab biosimilar, supplied as Q5099 (injection, ustekinumab-stba (Steqeyma), biosimilar, 1 mg). The patient presents to an outpatient infusion or injection suite in a dermatology or rheumatology clinic for a scheduled subcutaneous dose. Clinical workflow includes verification of prescription and prior authorization, medication preparation by pharmacy, clinical assessment for active infections or contraindications, informed consent, administration of the subcutaneous injection by a licensed clinician, observation for immediate adverse reactions (typically 15–30 minutes), documentation of lot number and dose in the medical record, and scheduling of the next maintenance dose.
Typical site of service is an outpatient clinic or physician office (dermatology, rheumatology, or specialty biologic injection center). Common patient scenarios include initiation after induction with weight-based dosing or ongoing maintenance dosing at manufacturer-specified intervals for conditions such as plaque psoriasis, psoriatic arthritis, or Crohn disease.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Standard — no modifier | Use when no special circumstances apply to the service. |
| | Increased procedural services | Use when work required to administer the injection is substantially greater than typical (rare for standard subcutaneous biologic but applicable if complex access or prolonged monitoring occurred).